CTI BioPharma Corp. [CTIC] fell -22.36% so far this year. What now?

CTI BioPharma Corp. [NASDAQ: CTIC] stock went on an upward path that rose over 6.38% on Thursday, amounting to a one-week price increase of more than 2.88%. The company report on April 22, 2021 that CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

CTI BioPharma Corp. (NASDAQ: CTIC) announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved on April 21, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received options to purchase an aggregate of 80,000 shares of CTI BioPharma common stock. The options will be issued upon each employee’s commencement of employment (the “Grant Date”), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee’s Grant Date, subject to the employee’s continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

Over the last 12 months, CTIC stock rose by 183.22%. The average equity rating for CTIC stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $222.67 million, with 74.67 million shares outstanding and 57.10 million shares in the current float. Compared to the average trading volume of 1.07M shares, CTIC stock reached a trading volume of 1466979 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on CTI BioPharma Corp. [CTIC]:

JMP Securities have made an estimate for CTI BioPharma Corp. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on June 24, 2020. While these analysts kept the previous recommendation, Lake Street raised their target price to Buy. The new note on the price target was released on March 05, 2019, representing the official price target for CTI BioPharma Corp. stock. Previously, the target price had yet another raise to $10, while Needham analysts kept a Buy rating on CTIC stock.

The Average True Range (ATR) for CTI BioPharma Corp. is set at 0.21 The Price to Book ratio for the last quarter was 4.63, with the Price to Cash per share for the same quarter was set at 0.59.

CTIC Stock Performance Analysis:

CTI BioPharma Corp. [CTIC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.88. With this latest performance, CTIC shares dropped by -16.11% in over the last four-week period, additionally sinking by -22.84% over the last 6 months – not to mention a rise of 183.22% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTIC stock in for the last two-week period is set at 44.03, with the RSI for the last a single of trading hit 48.06, and the three-weeks RSI is set at 42.65 for CTI BioPharma Corp. [CTIC]. The present Moving Average for the last 50 days of trading for this stock 2.96, while it was recorded at 2.38 for the last single week of trading, and 2.63 for the last 200 days.

Insight into CTI BioPharma Corp. Fundamentals:

Return on Total Capital for CTIC is now -119.99, given the latest momentum, and Return on Invested Capital for the company is -145.77. Return on Equity for this stock declined to -164.64, with Return on Assets sitting at -100.36. When it comes to the capital structure of this company, CTI BioPharma Corp. [CTIC] has a Total Debt to Total Equity ratio set at 18.61. Additionally, CTIC Total Debt to Total Capital is recorded at 15.69, with Total Debt to Total Assets ending up at 12.79. Long-Term Debt to Equity for the company is recorded at 2.00, with the Long-Term Debt to Total Capital now at 1.69.

Reflecting on the efficiency of the workforce at the company, CTI BioPharma Corp. [CTIC] managed to generate an average of -$2,280,478 per employee.CTI BioPharma Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.20.


With the latest financial reports released by the company, CTI BioPharma Corp. posted -0.2/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -53.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CTIC.

CTI BioPharma Corp. [CTIC] Insider Position Details

There are presently around $109 million, or 50.70% of CTIC stock, in the hands of institutional investors. The top three institutional holders of CTIC stocks are: ORBIMED ADVISORS LLC with ownership of 9,520,600, which is approximately 0% of the company’s market cap and around 0.50% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 7,140,450 shares of the stock with an approximate value of $17.85 million in CTIC stocks shares; and BVF INC/IL, currently with $17.32 million in CTIC stock with ownership of nearly 0% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in CTI BioPharma Corp. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 41 institutional holders increased their position in CTI BioPharma Corp. [NASDAQ:CTIC] by around 7,000,226 shares. Additionally, 13 investors decreased positions by around 2,891,913 shares, while 12 investors held positions by with 33,799,753 shares. The mentioned changes placed institutional holdings at 43,691,892 shares, according to the latest SEC report filing. CTIC stock had 29 new institutional investments in for a total of 5,938,997 shares, while 4 institutional investors sold positions of 81,619 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam